相关实验视频

Updated: Jan 9, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

哈米因通过向二酶4D和诱导铁灭菌来抑制非小细胞肺癌的生长

Jinrong He¹, Qi Xiong², Yu Qi³

¹Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Phytomedicine : international journal of phytotherapy and phytopharmacology

|December 4, 2025

概括

哈米因通过向PDE4D和抑制PI3K-Akt-Nrf2通路,诱导非小细胞肺癌 (NSCLC) 的铁亡. 这种天然化合物显示出作为一种新的NSCLC治疗策略的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

非小细胞肺癌 (NSCLC) 具有显著的死亡风险,耐治疗性需要新的治疗方法.
铁亡,一种独特的细胞死亡模式,呈现出一种潜在的策略,以克服对基于亡的疗法的抗性.
哈尔 (HM) 是一种天然的类化合物,已显示出抗瘤特性,但其在NSCLC中的疗效和机制在很大程度上仍未被探索.

研究的目的:

为了研究harmine的抗NSCLC作用.
确定分子标并阐明哈米因的作用机制,特别关注铁灭症的诱导.

主要方法:

通过各种测试 (CCK-8,殖民地形成,伤口愈合,Transwell,EDU,流细胞计) 评估了harmine对NSCLC细胞增殖,迁移和细胞周期的影响.
通过qPCR和西部斑点量化铁灭标志物 (ROS,铁,脂质过氧化,GPX4,SLC7A11);评估PI3K-Akt-Nrf2信号传递.
综合网络药理学,分子对接和CETSA用于目标识别;通过共免疫沉确认了PDE4D-PI3K相互作用,并通过基因操纵和救援实验验验证了PDE4D的作用.

主要成果:

哈米因抑制了NSCLC细胞的增殖和迁移,诱导G0/G1的停止,并促进了亡,同时触发了铁亡,由铁的增加,脂质过氧化和改变的标记表达 (PTGS2,ACSL4,LPCAT3,GPX4,SLC7A11,Nrf2) 证明.
通过Ferrostatin-1逆转证实了铁灭诱导;损害直接向的PDE4D,破坏PI3K相互作用并抑制PI3K-Akt-Nrf2通路.
在体内研究表明,在NSCLC异种移植模型中,harmine显著抑制了瘤生长,没有明显的全身毒性.

结论:

哈米因通过直接向PDE4D和抑制PI3K-Akt-Nrf2通路来诱导铁亡,在NSCLC中发挥抗瘤作用.
PDE4D成为NSCLC的新疗法标.
哈米恩代表了未来NSCLC治疗策略的有希望的候选人.

关键词:

铁性化 (ferroptosis) 是一种伤害我的伤害我的在NSCLCLC中,我们可以看到.这是一个PDE4D.通过PI3K-Akt-Nrf2路径.

更多相关视频

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...